Literature DB >> 31660588

Interaction of adenovirus with antibodies, complement, and coagulation factors.

Rondine J Allen1, Andrew P Byrnes1.   

Abstract

Adenovirus (AdV) is one of the most widely used vectors for gene therapy and vaccine studies due to its excellent transduction efficiency, capacity for large transgenes, and high levels of gene expression. When administered intravascularly, the fate of AdV vectors is heavily influenced by interactions with host plasma proteins. Some plasma proteins can neutralize AdV, but AdV can also specifically bind plasma proteins that protect against neutralization and preserve activity. This review summarizes the plasma proteins that interact with AdV, including antibodies, complement, and vitamin K-dependent coagulation factors. We will also review the complex interactions of these plasma proteins with each other and with cellular proteins, as well as strategies for developing better AdV vectors that evade or manipulate plasma proteins. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  adenovirus; complement; gene therapy; immunoglobulin G; immunoglobulin M; natural antibody; tripartite motif-containing protein 21; vitamin K-dependent coagulation factors

Mesh:

Substances:

Year:  2019        PMID: 31660588     DOI: 10.1002/1873-3468.13649

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  14 in total

Review 1.  Humoral First-Line Mucosal Innate Defence in vivo.

Authors:  Carl Persson
Journal:  J Innate Immun       Date:  2020-03-23       Impact factor: 7.349

Review 2.  Emerging roles of the complement system in host-pathogen interactions.

Authors:  Sanjaya K Sahu; Devesha H Kulkarni; Ayse N Ozanturk; Lina Ma; Hrishikesh S Kulkarni
Journal:  Trends Microbiol       Date:  2021-09-29       Impact factor: 17.079

Review 3.  Innate immune surveillance of the circulation: A review on the removal of circulating virions from the bloodstream.

Authors:  Stephanie E Ander; Frances S Li; Kathryn S Carpentier; Thomas E Morrison
Journal:  PLoS Pathog       Date:  2022-05-05       Impact factor: 7.464

Review 4.  Adenovirus-Extracellular Protein Interactions and Their Impact on Innate Immune Responses by Human Mononuclear Phagocytes.

Authors:  Coraline Chéneau; Eric J Kremer
Journal:  Viruses       Date:  2020-11-26       Impact factor: 5.048

5.  The FDA-Approved Drug Nelfinavir Inhibits Lytic Cell-Free but Not Cell-Associated Nonlytic Transmission of Human Adenovirus.

Authors:  Fanny Georgi; Vardan Andriasyan; Robert Witte; Luca Murer; Silvio Hemmi; Lisa Yu; Melanie Grove; Nicole Meili; Fabien Kuttler; Artur Yakimovich; Gerardo Turcatti; Urs F Greber
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

6.  Structure-Based Modeling of Complement C4 Mediated Neutralization of Adenovirus.

Authors:  Corey C Emerson; Phoebe L Stewart
Journal:  Viruses       Date:  2021-01-15       Impact factor: 5.048

7.  iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy.

Authors:  Dominik Brücher; Nicole Kirchhammer; Sheena N Smith; Jatina Schumacher; Nina Schumacher; Jonas Kolibius; Patrick C Freitag; Markus Schmid; Fabian Weiss; Corina Keller; Melanie Grove; Urs F Greber; Alfred Zippelius; Andreas Plückthun
Journal:  Mol Ther Methods Clin Dev       Date:  2021-01-20       Impact factor: 6.698

8.  The RGD-binding integrins αvβ6 and αvβ8 are receptors for mouse adenovirus-1 and -3 infection.

Authors:  Manuela Bieri; Rodinde Hendrickx; Michael Bauer; Bin Yu; Tania Jetzer; Birgit Dreier; Peer R E Mittl; Jens Sobek; Andreas Plückthun; Urs F Greber; Silvio Hemmi
Journal:  PLoS Pathog       Date:  2021-12-15       Impact factor: 6.823

Review 9.  Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer.

Authors:  Rebeca Gonzalez-Pastor; Peter S Goedegebuure; David T Curiel
Journal:  Cancer Gene Ther       Date:  2020-09-19       Impact factor: 5.987

Review 10.  Immune Responses to Viral Gene Therapy Vectors.

Authors:  Jamie L Shirley; Ype P de Jong; Cox Terhorst; Roland W Herzog
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.